Pierre Legault
Chief Executive Officer and President
Pierre Legault joined NephroGenex in October 2013 as Chief Executive Officer and has been a member of the Company’s Board of Directors since November 2012. Mr. Legault formerly served as CEO of Prosidion Ltd., a mid-size U.K. biotechnology firm.
Mr. Legault has also served as Executive VP, Chief Financial Officer and Treasurer of OSI Pharmaceuticals, Senior Executive VP and Chief Administrative Officer of Rite Aid Corporation, and President of the Eckerd Group, with overall managerial responsibilities for the Brooks Eckerd operations in the U.S. Mr. Legault also held several senior positions with Sanofi-Aventis and predecessor companies.
Mr. Legault has served on the boards of Forest Laboratories, Inc. and Cyclacel Pharmaceutical Inc. He studied at McGill University, University of Montreal (HEC) and the Harvard Business School, and holds a Six Sigma Green Belt, a BAA, MBA, CA and CPA diploma.
Dr. Jaikrishna Patel, BSc(Hons), MBBS(Hons), MRCP(UK)
Chief Scientific Officer
Jaikrishna Patel BSc(Hons), MBBS(Hons), MRCP(UK) joined NephroGenex in July 2015.
Dr. Patel has held numerous positions of increasing responsibility at GlaxoSmithKline and its predecessor companies, most recently serving as Vice President of Cardiovascular and Metabolism, Global Regulatory Affairs. In his prior roles, he also served as Vice President of Clinical Research and Medical Affairs in the Cardiovascular and Metabolism Therapeutic Area. Dr. Patel earned his Bachelor of Science in Experimental Pathology from University of London and completed his undergraduate and postgraduate medical training at St. Bartholomew’s Hospital and Kings College Hospital in London.
John P. Hamill
Chief Financial Officer
John P. Hamill joined NephroGenex as Chief Financial Officer in January 2014. Previously, he served as Co-President and Chief Financial Officer of Savient Pharmaceuticals, Inc. and as Senior Vice President and Chief Financial Officer of Savient. Mr. Hamill has also served as a financial consultant for various private companies. From 2001 until 2009, Mr. Hamill worked for PharmaNet Development Group, Inc., where he served as Executive Vice President and Chief Financial Officer from 2006 until 2009.
Mr. Hamill earned a B.S. with a dual major in Accounting/Business and Computer Science from DeSales University (formerly Allentown College of St. Francis de Sales) in 1986. He is a Certified Public Accountant and is affiliated with the Pennsylvania Institute of Certified Public Accountants and the American Institute of Certified Public Accountants.
Bob Peterson
Vice President of Product Development and Regulatory Affairs
Bob Peterson was named Vice President of Product Development and Regulatory Affairs of NephroGenex in 2009. He has over 27 years of product development experience in the pharmaceutical and cardiovascular implant industry.
Prior to joining the Company, Mr. Peterson served as Director of Research and Development of Cardiopolymers, Inc. (currently LoneStar Heart Inc.), where he oversaw development of novel biopolymer therapy for heart failure. From 1999 to 2006, Mr. Peterson served as Director of Product Development for BioStratum, Inc., where he led development of biopharma candidates from concept to early clinical trials. From 1986-1999 he led the development of a line of vascular and endovascular grafts at Baxter International.
Early in his career, Mr. Peterson served as an officer in the United States Army. He graduated from the United States Military Academy at West Point and received his Master of Engineering Degree at the University of California, Berkeley.
Pepper Landson
Vice President of Clinical Operations
Pepper Landson has served as Vice President of Clinical Operations since 2011. Ms. Landson has over 21 years of clinical research industry experience. From 1999 to 2011, she worked as Principal Consultant of Cheval Noir Inc., advising clients on clinical development and operations. She built the clinical operations department for an Ohio-based oncology diagnostics company that was acquired after a successful NDA submission. Her expertise and counsel have positively affected global clinical development efforts in the areas of oncology, diabetes, neurology, infertility, and HIV.
From 1996 to 1998, Ms. Landson worked as a Project Manager and Research Associate for British Biotech developing a first generation anti-angiogenesis agent. From 1993 to 1996, she managed clinical research activities for the U.S. Military.
Ms. Landson received a B.S. in Television, Radio and Film Management from Syracuse University, and a B.S. in Life Sciences from Marymount University.